Transcenta's osemitamab (TST001) demonstrated a median PFS of 12.6 months in G/GEJ cancer patients with high/medium Claudin18.2 expression when combined with checkpoint inhibitors and CAPOX.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.